NASDAQ:ALNY Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free ALNY Stock Alerts $143.71 -0.09 (-0.06%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$141.98▼$145.7950-Day Range$143.80▼$162.8152-Week Range$141.98▼$218.88Volume489,263 shsAverage Volume780,202 shsMarket Capitalization$18.10 billionP/E RatioN/ADividend YieldN/APrice Target$215.88 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alnylam Pharmaceuticals alerts: Email Address Alnylam Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside50.2% Upside$215.88 Price TargetShort InterestHealthy1.98% of Shares Sold ShortDividend StrengthN/ASustainability-1.52Upright™ Environmental ScoreNews Sentiment0.30Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.46) to ($2.16) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.68 out of 5 starsMedical Sector71st out of 908 stocksPharmaceutical Preparations Industry24th out of 424 stocks 4.3 Analyst's Opinion Consensus RatingAlnylam Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.59, and is based on 10 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageAlnylam Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.98% of the outstanding shares of Alnylam Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAlnylam Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alnylam Pharmaceuticals has recently decreased by 10.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlnylam Pharmaceuticals does not currently pay a dividend.Dividend GrowthAlnylam Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlnylam Pharmaceuticals has received a 63.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Gene therapy medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alnylam Pharmaceuticals is -1.52. Previous Next 1.8 News and Social Media Coverage News SentimentAlnylam Pharmaceuticals has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Alnylam Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 6 people have searched for ALNY on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Alnylam Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alnylam Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Alnylam Pharmaceuticals is held by insiders.Percentage Held by Institutions92.97% of the stock of Alnylam Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alnylam Pharmaceuticals are expected to grow in the coming year, from ($4.46) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alnylam Pharmaceuticals is -40.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alnylam Pharmaceuticals is -40.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About Alnylam Pharmaceuticals Stock (NASDAQ:ALNY)Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.Read More ALNY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALNY Stock News HeadlinesApril 26, 2024 | markets.businessinsider.comEQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest ratesApril 25, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (ALNY) Scheduled to Post Earnings on ThursdayApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 21, 2024 | americanbankingnews.comAlnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 12-Month Low at $143.50April 21, 2024 | americanbankingnews.comStockNews.com Downgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) to HoldApril 19, 2024 | benzinga.comHow Is The Market Feeling About Alnylam Pharmaceuticals?April 18, 2024 | businesswire.comAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsApril 17, 2024 | stocknews.com3 Biotech Stocks Paving the Way for Bullish Investment GainsApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 17, 2024 | markets.businessinsider.comLevi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNYApril 11, 2024 | benzinga.comRegeneron Pharmaceuticals's Options: A Look at What the Big Money is ThinkingApril 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharma on Strong Zilebesiran Trial Results and Lucrative Roche PartnershipApril 8, 2024 | msn.comWegovy Helps HFpEF Patients With Diabetes MellitusApril 8, 2024 | msn.comStudy shows promise of zilebesiran injection in reducing systolic blood pressureApril 8, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Alnylam Pharma (ALNY)April 7, 2024 | markets.businessinsider.comAlnylam Presents Positive Results From KARDIA-2 Phase 2 Study Of Zilebesiran At ACCApril 7, 2024 | businesswire.comAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionApril 6, 2024 | finance.yahoo.comThose who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%April 5, 2024 | bizjournals.comAlnylam CEO’s total pay nearly doubles, hitting $8.9MApril 3, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Sutro Biopharma (STRO)April 3, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Aptose Biosciences (APTO)April 2, 2024 | benzinga.com$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much TodayMarch 26, 2024 | markets.businessinsider.comDecoding 12 Analyst Evaluations For Regeneron PharmaceuticalsMarch 25, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS PipelineMarch 20, 2024 | businesswire.comAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionMarch 19, 2024 | finance.yahoo.comRapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of DirectorsMarch 19, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Tenaya Therapeutics (TNYA)See More Headlines Receive ALNY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/25/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALNY CUSIP02043Q10 CIK1178670 Webwww.alnylam.com Phone(617) 551-8200Fax617-551-8101Employees2,100Year Founded2002Price Target and Rating Average Stock Price Target$216.12 High Stock Price Target$395.00 Low Stock Price Target$161.00 Potential Upside/Downside+50.4%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($3.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-440,240,000.00 Net Margins-24.08% Pretax Margin-23.71% Return on EquityN/A Return on Assets-12.18% Debt Debt-to-Equity RatioN/A Current Ratio3.08 Quick Ratio2.99 Sales & Book Value Annual Sales$1.83 billion Price / Sales9.90 Cash FlowN/A Price / Cash FlowN/A Book Value($1.76) per share Price / Book-81.65Miscellaneous Outstanding Shares125,950,000Free Float124,057,000Market Cap$18.10 billion OptionableOptionable Beta0.39 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Yvonne L. Greenstreet M.B.A. (Age 61)MBChB, CEO & Director Comp: $2.15MMr. Jeffrey V. Poulton M.B.A. (Age 56)CFO & Executive VP Comp: $1.05MDr. Akshay K. Vaishnaw M.D. (Age 61)Ph.D., Chief Innovation Officer & Member of the Scientific Advisory Board Comp: $1.12MDr. Pushkal P. Garg M.D. (Age 56)Chief Medical Officer and Executive VP of Development & Medical Affairs Comp: $1.06MMr. Tolga Tanguler M.B.A. (Age 51)Executive VP & Chief Commercial Officer Comp: $971.3kMr. Timothy J. MainesChief Technical Operations & Quality OfficerDr. Kevin Joseph Fitzgerald Ph.D. (Age 55)Senior VP, Head of Research & Chief Scientific Officer Ms. Christine Regan Lindenboom (Age 43)Senior VP of Investor Relations & Corporate Communications Mr. Piyush Sharma J.D.Chief Ethics & Compliance OfficerMr. Evan Lippman M.B.A.Chief Corporate Development & Strategy OfficerMore ExecutivesKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNRoyalty PharmaNASDAQ:RPRXMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRHorizon Therapeutics PublicNASDAQ:HZNPView All CompetitorsInsiders & InstitutionsSimplex Trading LLCSold 7,600 shares on 4/25/2024Ownership: 0.000%Zurcher Kantonalbank Zurich Cantonalbank Bought 4,934 shares on 4/25/2024Ownership: 0.040%Fjarde AP Fonden Fourth Swedish National Pension FundSold 500 shares on 4/25/2024Ownership: 0.022%Lindbrook Capital LLCSold 133 shares on 4/25/2024Ownership: 0.000%Simplicity Wealth LLCBought 1,934 shares on 4/24/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ALNY Stock Analysis - Frequently Asked Questions Should I buy or sell Alnylam Pharmaceuticals stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALNY shares. View ALNY analyst ratings or view top-rated stocks. What is Alnylam Pharmaceuticals' stock price target for 2024? 17 brokers have issued 1 year target prices for Alnylam Pharmaceuticals' shares. Their ALNY share price targets range from $161.00 to $395.00. On average, they expect the company's share price to reach $215.88 in the next year. This suggests a possible upside of 50.2% from the stock's current price. View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts. How have ALNY shares performed in 2024? Alnylam Pharmaceuticals' stock was trading at $191.41 at the beginning of the year. Since then, ALNY stock has decreased by 24.9% and is now trading at $143.71. View the best growth stocks for 2024 here. Are investors shorting Alnylam Pharmaceuticals? Alnylam Pharmaceuticals saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 2,500,000 shares, a drop of 10.7% from the March 31st total of 2,800,000 shares. Based on an average trading volume of 836,100 shares, the short-interest ratio is currently 3.0 days. View Alnylam Pharmaceuticals' Short Interest. When is Alnylam Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our ALNY earnings forecast. How can I listen to Alnylam Pharmaceuticals' earnings call? Alnylam Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link. How were Alnylam Pharmaceuticals' earnings last quarter? Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its earnings results on Thursday, February, 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.20) by $0.10. The biopharmaceutical company earned $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. The firm's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the business earned ($1.68) earnings per share. What ETFs hold Alnylam Pharmaceuticals' stock? ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Morningstar US Small Growth (MSGR), Amplify Treatments, Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), Principal Healthcare Innovators ETF (BTEC), Fidelity Disruptive Medicine ETF (FMED), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX) and Tema Cardiovascular and Metabolics ETF (HRTS). What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings? Alnylam Pharmaceuticals issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.7 billion-$1.9 billion, compared to the consensus revenue estimate of $1.8 billion. What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO? 65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alnylam Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD). Who are Alnylam Pharmaceuticals' major shareholders? Alnylam Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.23%), Simplex Trading LLC (0.00%), Assenagon Asset Management S.A. (0.05%), Portman Square Capital LLP (0.00%), Zurcher Kantonalbank Zurich Cantonalbank (0.04%) and Fjarde AP Fonden Fourth Swedish National Pension Fund (0.02%). Insiders that own company stock include Akshay Vaishnaw, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Michael W Bonney, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet. View institutional ownership trends. How do I buy shares of Alnylam Pharmaceuticals? Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALNY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeFed launches fourth dollar overhaulStansberry ResearchThe World's First "$20 Trillion Drug?"Behind the MarketsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsI’m afraid WWIII is a very real possibility Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.